Alan L Niederman
About
Dr. Alan Niederman is an interventional and structural cardiologist practicing in Fort Lauderdale, Florida. He is affiliated with Broward Health Physician Group, where his clinical work focuses on interventional cardiology.
His research activity spans clinical trials examining anticoagulation strategies, coronary stenting techniques, and novel therapies for acute myocardial infarction and chronic heart failure. He has contributed as a principal investigator at the Greater Fort Lauderdale Heart Group Research clinical center, and his work has appeared in journals including the Journal of the American College of Cardiology, The Lancet, and the American Heart Journal. Among the studies he has been involved with are multicenter trials evaluating percutaneous coronary intervention protocols, fibrinolytic agents, and cardiac cell therapy in post-infarction heart failure patients.
Dr. Niederman holds board certification in both internal medicine and interventional cardiology and is licensed in Florida.
Credentials
Publications
- A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction.
- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
- Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial).
- Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial.
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
- Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
- Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
- Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
- Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group.
- Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension.
Request CV and rates
Tell us about your case and we'll connect you with Alan L Niederman within two business days.
Other Internal Medicine experts
Verified specialists available for your case.
